EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY 4.0

Incidence of pneumonitis following the use of different anaplastic lymphoma kinase tyrosine kinase inhibitor regimens: An updated systematic review and meta‐analysis

Wenting Qie iD, Qian Zhao iD, Linlin Yang, Bing Zou, Yanan Duan iD, YueYuan Yao, Linlin Wang iD

Cancer Medicine · 2023-07 · 12 (13) · 13873-13884

DOI: 10.1002/cam4.5913 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Cancer Medicine, online erschienen am 05.04.2023. Verfasst von Wenting Qie und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Weifang Medical University, Weifang, Shandong, People's Republic of China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pneumonia, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK TKIs) have shown remarkable clinical activity in patients with non‐small‐cell lung cancer (NSCLC). However, pneumonitis is a serious side effect of ALK TKIs in NSCLC patients. In this meta‐analysis, we aimed to determine the incidence of ALK‐TKI‐associated pneumonitis. Materials and Methods We searched electronic databases to identify relevant studies published until August 2022. The incidence of pneumonitis was calculated using a fixed‐effects model when no substantial heterogeneity was observed. Otherwise, a random‐effects model was used. Subgroup analyses of different treatment groups were performed. Statistical analyses were conducted using STATA 17.0.

Results

Twenty‐six clinical trials involving 4752 patients were eligible for analysis. All‐grade pneumonitis incidence was 2.92% (95% confidence interval [CI]: 1.79%–4.27%), high‐grade (Grade 3–4) pneumonitis incidence was 1.42% (95% CI: 0.84%–2.12%) and Grade 5 pneumonitis incidence was 0.09% (95% CI: 0.00%–0.28%). The subgroup analysis showed that brigatinib was associated with the highest incidence of both all‐grade and high‐grade pneumonitis (7.09% and 3.06%, respectively). ALK TKI treatment after chemotherapy was associated with a higher incidence of all‐grade and high‐grade pneumonitis than first‐line ALK TKI treatment (7.73% vs. 2.26% and 3.64% vs. 1.26%, respectively). Cohorts from Japanese trials had a higher incidence of all‐grade and high‐grade pneumonitis.

Conclusion

Our study provides precise data on the incidence of pneumonitis in patients receiving treatment with ALK TKIs. Overall, ALK TKIs have tolerable pulmonary toxicity. Early pneumonitis identification and treatment are required to prevent further deterioration in patients receiving treatment with brigatinib and in those who received prior chemotherapy, particularly in the Japanese population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsPneumoniaDrug-Related Side Effects and Adverse ReactionsHumansProtein-Tyrosine KinasesAnaplastic Lymphoma KinaseTyrosine Kinase InhibitorsIncidenceProtein Kinase InhibitorsOrganophosphorus CompoundsPyrimidines

Stichwörter der Autor:innen

ALK TKIsNSCLClung toxicitymeta-analysispneumonitis

Substanzen

Protein-Tyrosine KinasesAnaplastic Lymphoma KinaseTyrosine Kinase InhibitorsProtein Kinase InhibitorsbrigatinibOrganophosphorus CompoundsPyrimidines

Autor:innen und Institutionen

  • Department of Oncology, Weifang Medical University, Weifang, Shandong, People's Republic of China.
  • Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, People's Republic of China.
  • Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, People's Republic of China.

ORCID-Profile: Wenting Qie, Qian Zhao, Yanan Duan, Linlin Wang

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Shandong Province

Zitieren

APA

Qie, W., Zhao, Q., Yang, L., Zou, B., Duan, Y., Yao, Y., & Wang, L. (2023). Incidence of pneumonitis following the use of different anaplastic lymphoma kinase tyrosine kinase inhibitor regimens: An updated systematic review and meta‐analysis. Cancer Medicine, 12(13), 13873-13884. https://doi.org/10.1002/cam4.5913

Vancouver

Qie W, Zhao Q, Yang L, Zou B, Duan Y, Yao Y, et al. Incidence of pneumonitis following the use of different anaplastic lymphoma kinase tyrosine kinase inhibitor regimens: An updated systematic review and meta‐analysis. Cancer Medicine. 2023;12(13):13873-13884. doi:10.1002/cam4.5913

BibTeX
@article{Qie2023,
  author = {Qie, Wenting and Zhao, Qian and Yang, Linlin and Zou, Bing and Duan, Yanan and Yao, YueYuan and Wang, Linlin},
  title = {Incidence of pneumonitis following the use of different anaplastic lymphoma kinase tyrosine kinase inhibitor regimens: An updated systematic review and meta‐analysis},
  journal = {Cancer Medicine},
  year = {2023},
  volume = {12},
  number = {13},
  pages = {13873--13884},
  doi = {10.1002/cam4.5913}
}
Kostenlos starten →